October 13, 2017 11:26am
The pre-market indication was ... a positive +$6.25 or +7.25% … the fickle finger of sector and market acceptance
The FDA Advisory committee unanimously recommended approval of Investigational LUXTURNA™ (voretigene neparvovec) for patients with Biallelic RPE65-mediated Inherited Retinal Disease